Finance

Lists
Why is 2359 down 2,19%?
Dive Deeper
2359:HKG
WuXi AppTec Ord Shs H
196,20 HKD
-2,19%
(-4,40) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
203,80 HKD
High
209,00 HKD
Low
185,00 HKD
Mkt. cap
544,52 მლრ.
Avg. vol.
3,91 მლნ.
Volume
10,16 მლნ.
Dividend
1,22%
Quarterly dividend
0,60 HKD
Ex-dividend date
4 სექ. 2026
P/E ratio
23,98
52-wk high
219,20 HKD
52-wk low
96,70 HKD
EPS
8,18 HKD
No. of employees
36 ათ.
Open
203,80 HKD
High
209,00 HKD
Low
185,00 HKD
Mkt. cap
544,52 მლრ.
Avg. vol.
3,91 მლნ.
Volume
10,16 მლნ.
Dividend
1,22%
Quarterly dividend
0,60 HKD
Ex-dividend date
4 სექ. 2026
P/E ratio
23,98
52-wk high
219,20 HKD
52-wk low
96,70 HKD
EPS
8,18 HKD
No. of employees
36 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
12 საათის წინ
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOსტივ იანგ | გე ლი
Employees35,6 ათ.
Founded1 დეკ. 2000
Headquarters-
SectorHealth care
Last report
3 აგვ. 2026
Fiscal period
Q2 2026
2,20 CNY / 1,34 CNY
+64,18%beat
Revenue / Est. (CNY)
16,46 მლრდ. / 12,86 მლრდ.
+28,03%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
12,04 მლრდ.
10,97 მლრდ.
12,44 მლრდ.
16,46 მლრდ.
Cost of goods sold
6,07 მლრდ.
4,91 მლრდ.
6,17 მლრდ.
-
Cost of revenue
6,07 მლრდ.
4,91 მლრდ.
6,17 მლრდ.
-
Research and development expenses
311,73 მლნ.
236,94 მლნ.
266,96 მლნ.
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
854,49 მლნ.
853,67 მლნ.
891,80 მლნ.
-
Operating expense
1,38 მლრდ.
1,26 მლრდ.
1,22 მლრდ.
-
Total operating expenses
7,45 მლრდ.
6,17 მლრდ.
7,39 მლრდ.
-
Operating income
4,59 მლრდ.
4,80 მლრდ.
5,04 მლრდ.
-
Other non operating income
-470,36 მლნ.
281,37 მლნ.
-266,37 მლნ.
-
EBT including unusual items
5,13 მლრდ.
6,75 მლრდ.
5,61 მლრდ.
-
EBT excluding unusual items
5,11 მლრდ.
6,95 მლრდ.
5,19 მლრდ.
-
Income tax expense
1,55 მლრდ.
1,09 მლრდ.
936,77 მლნ.
-
Effective tax rate
30,19%
16,12%
16,71%
-
Other operating expenses
57,96 მლნ.
25,84 მლნ.
726,05 ათ.
-
Net income
3,51 მლრდ.
7,08 მლრდ.
4,65 მლრდ.
-
Net profit margin
29,18%
64,49%
37,40%
-
Earnings per share
1,24
1,42
1,57
2,20
Interest and investment income
1,21 მლრდ.
1,87 მლრდ.
439,82 მლნ.
-
Interest expense
-226,71 მლნ.
-
-30,95 მლნ.
-
Net interest expenses
981,72 მლნ.
1,87 მლრდ.
408,87 მლნ.
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 მლრდ.
5,61 მლრდ.
5,85 მლრდ.
-
Gain or loss from assets sale
-158,03 მლნ.
218,40 მლნ.
-
-
AI content may include mistakes. Learn more
Google აპები